In reply to: Enalapril and the VEGFA gene: personalized medicine in hypertension therapy

We appreciate the constructive comments by Sahoo et al. regarding our recent article [1]. The raised concerns are common and important issues in genetic studies addressing the possible association of particular phenotypes and genetic markers. As mentioned by Sahoo et al., we reported on polymorphisms in the vascular endothelial growth factor A (VEGFA) gene affecting the antihypertensive responses to enalapril, a commonly used angiotensin...